In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome

Abstract excerpt

Chimeric antigen receptor (CAR) T cells brought substantial benefit to patients with B-cell malignancies. Notwithstanding, CAR T-cell manufacturing requires complex procedures impeding the broad supply chain. Here, we provide evidence that human CD19-CAR T cells can be generated directly in vivo using the lentiviral vector CD8-LV specifically targeting human CD8 + cells. Administration into mice xenografted with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CAR-T cell therapy research
• Share to Immune Cell Function and Interaction
• Share to T-cell and B-cell Immunology